+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 21 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.

Age: 18Years +All GendersPhase 3
245 locations
S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
R

Actively Recruiting

Researchers are evaluating tulisokibart as a treatment for radiographic axial spondyloarthritis r-axSpA, a type of arthritis causing pain, stiffness, and inflammation in the spine and pelvis joints. This condition leads to damage visible on X-rays. The study aims to find out if different doses of tulisokibart improve symptoms better than a placebo, which looks like the medicine but contains no active drug. Participants will be assigned to one of four groups a high dose, medium dose, low dose of tulisokibart, or a placebo. After 16 weeks, those on the low dose or placebo will be randomly reassigned to receive either the medium or high dose. The study includes a 16-week placebo-controlled period followed by a 124-week long-term extension, which consists of a 40-week main extension and an 84-week optional extension. Tulisokibart is given through subcutaneous injections. During the study, participants will undergo assessments of their arthritis symptoms using various scales and imaging, including MRI scans of the spine and pelvis. Researchers will monitor changes in pain, function, disease activity, and fatigue at baseline and after 16 weeks. Safety will be tracked throughout the study and for up to about 154 weeks. The study is scheduled to complete in early 2030.

Age: 18Years - 80YearsAll GendersPhase 2
107 locations
P

Actively Recruiting

Researchers are evaluating budoprutug, a humanized monoclonal antibody targeting CD19, in adults with immune thrombocytopenia ITP, a condition characterized by low platelet counts. This Phase 1b2a open-label study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical effects of budoprutug in patients with platelet counts below 30,000L despite prior treatment attempts. The study is sponsored by Climb Bio, Inc. Participants will receive budoprutug as two intravenous infusions administered 14 days apart. The study includes sequential cohorts with escalating doses, followed by a dose expansion group. Each participant receives a single IV dose on Day 1 and another on Day 15. The trial monitors the effects of budoprutug on platelet counts and CD20 B-cell levels, among other factors. Throughout the study, participants will be closely monitored up to 48 weeks for treatment-related side effects, blood levels of the drug, immune cell changes, platelet responses, and the development of anti-drug antibodies. Safety labs including coagulation tests and bilirubin levels will be assessed. The study does not include placebo groups and participation involves scheduled visits for infusions and follow-up evaluations to track both safety and preliminary clinical outcomes over nearly a year.

Age: 18Years +All GendersPhase 1Phase 2
20 locations
P

Actively Recruiting

Researchers are conducting a multinational, multicenter, open-label Phase III study to evaluate the efficacy and safety of Radotinib in adults with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia CP-CML who have experienced failure or intolerance to prior tyrosine kinase inhibitor TKI therapies, including Imatinib. This study aims to understand how Radotinib performs in this patient population where previous treatments have not been successful or tolerated. Participants will receive Radotinib 400 mg orally twice daily for 12 months. Dose adjustments to 600 mg or 400 mg twice daily are permitted if participants experience hematologic or non-hematologic toxicities that resolve within specified time frames. This is a single-arm study with no placebo or comparator group, involving continuous administration of the study drug throughout the treatment period. During the study, participants will be regularly monitored for responses such as major cytogenetic response at 6 months and other outcomes including complete cytogenetic response, major molecular response, overall survival, and progression-free survival up to 24 months. Safety and tolerability will also be assessed. The study enrollment started in 2018 and is expected to complete by mid-2028, with ongoing follow-up to assess long-term outcomes.

Age: 18Years +All GendersPhase 3
18 locations
P

Actively Recruiting

Researchers are evaluating calderasib alone and in combination with other therapies for people with advanced solid tumors that have a specific KRAS G12C mutation. The study is designed to assess the safety, how the body processes the drug pharmacokinetics, and the effectiveness of calderasib and its combinations. Participants have advanced cancers confirmed by specific tests and have often received prior treatments. Participants are assigned to one of several groups receiving different treatments. Some receive daily oral doses of calderasib alone with doses increasing up to 800 mg, adjusted as needed for safety. Others receive calderasib combined with pembrolizumab infusions every 21 days for up to 35 cycles 24 months, sometimes with additional chemotherapy drugs like carboplatin, pemetrexed, cetuximab, oxaliplatin, leucovorin, or 5-fluorouracil according to standard dosing schedules. Treatments continue until the disease progresses or participants stop. During the study, participants have regular visits for drug dosing and safety monitoring. Researchers track side effects, dose-limiting toxicities, and treatment discontinuations over months. Blood samples are taken at specific times to measure drug levels and how the body absorbs and clears calderasib. The main outcomes include safety measures up to about 56 months and response rates. This long study period helps understand how participants respond and tolerate the treatments over time.

Age: 18Years +All GendersPhase 1
75 locations
P

Actively Recruiting

Researchers are evaluating the combination of calderasib and pembrolizumab as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer NSCLC that has a specific KRAS G12C mutation and a PD-L1 tumor proportion score of 50% or higher. The study aims to determine if this combination improves progression-free survival compared to pembrolizumab with placebo. This is a phase 3 randomized, double-blind trial sponsored by Merck Sharp & Dohme LLC. Participants will receive pembrolizumab 200 mg through intravenous infusion on the first day of each 21-day cycle, continuing for up to 35 cycles. In addition, they will take either calderasib or placebo tablets daily until they meet discontinuation criteria. The study includes two groups one receiving calderasib plus pembrolizumab and the other receiving placebo plus pembrolizumab. No new participants will be offered a second course of pembrolizumab. Throughout the study, participants will undergo various assessments including tumor evaluations by central review to measure progression-free survival, overall survival, and response rates. Quality of life and physical functioning will be monitored using standardized questionnaires up to 24 months. Safety will be tracked by recording adverse events and treatment discontinuations for up to approximately 80 months. The total study duration extends up to 7 years, with ongoing monitoring throughout.

Age: 18Years +All GendersPhase 3
246 locations
P

Actively Recruiting

Researchers are evaluating new treatments for advanced non-small cell lung cancer NSCLC that has not been treated before and has spread beyond what surgery can remove. The study focuses on combining pembrolizumab, an immunotherapy, with or without chemotherapy, alongside other treatments including the antibody-drug conjugate HER3-DXd. The main goals are to assess how safe and effective these treatment combinations are for participants with stage IV NSCLC. Participants will receive pembrolizumab as an intravenous infusion every three weeks for up to two years. One study group will also receive standard platinum-based chemotherapy regimens tailored to their cancer type, while another group will receive the HER3-DXd antibody-drug conjugate infusion alongside pembrolizumab. Chemotherapy drugs like paclitaxel, nab-paclitaxel, carboplatin, and pemetrexed are given according to specific schedules and doses, with treatment continuing until certain stopping criteria are met. During the study, participants will undergo regular assessments to monitor treatment response and side effects over up to five years. Researchers will measure overall response rates, adverse events, and treatment discontinuation due to side effects. Secondary measures include duration of response, progression-free survival, and overall survival. The trial includes safety monitoring and long-term follow-up, with participants attending scheduled visits for evaluations and infusions throughout the study period.

Age: 18Years +All GendersPhase 2
41 locations
C

Actively Recruiting

Researchers are evaluating sacituzumab tirumotecan alone or combined with pembrolizumab to treat people with triple-negative breast cancer TNBC that is locally recurrent, unresectable, or metastatic and expresses PD-L1 at a combined positive score less than 10. The study aims to find out if these treatments help people live longer overall or delay cancer growth compared to chemotherapy chosen by their physician. This is a phase 3 randomized trial focused on treatment effectiveness and safety. Participants are randomly assigned to one of three groups sacituzumab tirumotecan given intravenously every two weeks sacituzumab tirumotecan every two weeks plus pembrolizumab every six weeks for up to about two years or physicians choice chemotherapy including options like paclitaxel, nab-paclitaxel, gemcitabine plus carboplatin with varying schedules. Pre-medications such as antihistamines, acetaminophen, and steroids are given before sacituzumab tirumotecan infusions to reduce side effects. During the study, participants receive assigned treatments until disease progression, toxicity, or discontinuation. Researchers monitor progression-free survival and overall survival up to about 39 and 61 months respectively. They also assess response rates, duration of response, quality of life changes using questionnaires, and record adverse events over the study period. The trial follows participants for extended periods to evaluate long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
283 locations

1-10 of 21

1